AMEX
8.28USD
+0.10 (+1.22%)
We have scored 13 news catalysts on Cybin Inc. (CYBN) over the past 12 months. The biggest single-day move next to one of them came Jul 15, 2026, when CYBN closed −6.6%: “Johnson & Johnson's Spravato sales growth supports psychedelic drug opportunity: Jefferies”. Coverage across the window leans negative (average ticker sentiment −0.28). Most of the impact sits in institutional appeal and price momentum.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
413M
P/E
—
EPS
—
Beta
0.79
52W range
4.81-10.7199
Day range
8.14–8.38
Open
8.28
Prev close
8.18
Volume
716.5K
Avg volume
874.4K
Dividend
0.00
IPO
2019-09-13
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about Cybin Inc. — not a sector bucket. Click an edge to see the articles that established the link.
Latest scored catalyst for CYBN: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Cybin Inc. is a biopharmaceutical firm dedicated to pioneering treatments that leverage psychedelic compounds. Its research and development portfolio encompasses several key candidates: CYB003, a modified psilocybin compound targeting major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine designed to alleviate anxiety conditions; and CYB005, a phenethylamine derivative aimed at combating neuroinflammation. Beyond its drug pipeline, Cybin has also conceived EMBARK, an innovative form of psychotherapy enhanced by psychedelics. The enterprise's primary base of operations is situated in Toronto, Canada.
